Skip to main content
Erschienen in: Tumor Biology 6/2014

01.06.2014 | Review

Genetic unraveling of colorectal cancer

verfasst von: Sabha Rasool, Vamiq Rasool, Tahira Naqvi, Bashir A. Ganai, Bhahwal Ali Shah

Erschienen in: Tumor Biology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer is a common disease in both men and women (being the third most common cancer in men and the second most common among women) and thus represents an important and serious public health issue, especially in the western world. Although it is a well-established fact that cancers of the large intestine produce symptoms relatively earlier at a stage that can be easily cured by resection, a large number of people lose their lives to this deadly disease each year. Recent times have seen an important change in the incidence of colorectal cancer in different parts of the world. The etiology of colorectal cancer is multifactorial and is likely to involve the actions of genes at multiple levels along the multistage carcinogenesis process. Exhaustive efforts have been made out in the direction of unraveling the role of various environmental factors, gene mutations, and polymorphisms worldwide (as well as in Kashmir—“a valley of gastrointestinal cancers”) that have got a role to play in the development of this disease so that antitumor drugs could be developed against this cancer, first, and, finally, the responsiveness or resistance to these agents could be understood for combating this global issue.
Literatur
1.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMed Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.PubMed
2.
Zurück zum Zitat Boyle P, Elena M. Epidemiology of colorectal cancer. British Med Bull. 2002;64:1–25. Boyle P, Elena M. Epidemiology of colorectal cancer. British Med Bull. 2002;64:1–25.
3.
Zurück zum Zitat World Health Organization (February 2006). Retrieved 24 May 2007. World Health Organization (February 2006). Retrieved 24 May 2007.
4.
Zurück zum Zitat Paula MC, Harold F. The genetics of CRC. Ann Intern Med. 2002;137:603–12. Paula MC, Harold F. The genetics of CRC. Ann Intern Med. 2002;137:603–12.
5.
Zurück zum Zitat Umar A, Greenwald P. Alarming colorectal cancer incidence trends: a case for early detection and prevention. Cancer Epidemiol Biomarkers Prev. 2009;18:1672–3.PubMed Umar A, Greenwald P. Alarming colorectal cancer incidence trends: a case for early detection and prevention. Cancer Epidemiol Biomarkers Prev. 2009;18:1672–3.PubMed
6.
Zurück zum Zitat Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–60.PubMed Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–60.PubMed
7.
Zurück zum Zitat Fatemi SR, Shivarani S, Malek FN, Vahedi M, Maserat E, Iranpour Y, et al. Colonoscopy screening results in at risk Iranian population. Asian Pac J Cancer Prev. 2010;11:1801–4.PubMed Fatemi SR, Shivarani S, Malek FN, Vahedi M, Maserat E, Iranpour Y, et al. Colonoscopy screening results in at risk Iranian population. Asian Pac J Cancer Prev. 2010;11:1801–4.PubMed
8.
Zurück zum Zitat Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol. 2012;4(4):71–5.PubMedCentralPubMed Moghimi-Dehkordi B, Safaee A. An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol. 2012;4(4):71–5.PubMedCentralPubMed
9.
Zurück zum Zitat Sameer AS, Shah ZA, Syeed N, Banday MZ, Bashir SM, Bhat BA, et al. TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genet Mol Res. 2010;9:651–60.PubMed Sameer AS, Shah ZA, Syeed N, Banday MZ, Bashir SM, Bhat BA, et al. TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genet Mol Res. 2010;9:651–60.PubMed
10.
Zurück zum Zitat Sameer AS, ul Rehman S, Pandith AA, Syeed N, Shah ZA, Chowdhri NA, et al. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol. 2009;15:244–52.PubMedCentralPubMed Sameer AS, ul Rehman S, Pandith AA, Syeed N, Shah ZA, Chowdhri NA, et al. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol. 2009;15:244–52.PubMedCentralPubMed
11.
Zurück zum Zitat Rasool S, Ganai BA, Sameer AS, Masood A. Esophageal cancer: associated factors with special reference to the Kashmir Valley. Tumori. 2012;98:191–203.PubMed Rasool S, Ganai BA, Sameer AS, Masood A. Esophageal cancer: associated factors with special reference to the Kashmir Valley. Tumori. 2012;98:191–203.PubMed
12.
Zurück zum Zitat Jenkins TD, Rustgi AK: Genetics of colorectal carcinoma. In: cancer of the lower gastrointestinal tract. Ed. Willet C.G. London 2001;33–44. Jenkins TD, Rustgi AK: Genetics of colorectal carcinoma. In: cancer of the lower gastrointestinal tract. Ed. Willet C.G. London 2001;33–44.
13.
Zurück zum Zitat Young GP, Hu Y, Le Leu RK, Nyskohus L. Dietary fibre and colorectal cancer: a model for environment–gene interactions. Mol Nutr Food Res. 2005;49(6):571–84.PubMed Young GP, Hu Y, Le Leu RK, Nyskohus L. Dietary fibre and colorectal cancer: a model for environment–gene interactions. Mol Nutr Food Res. 2005;49(6):571–84.PubMed
14.
Zurück zum Zitat Kinzler KW, Vogelstein B. Colorectal tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill; 2002. p. 583–612. Kinzler KW, Vogelstein B. Colorectal tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill; 2002. p. 583–612.
15.
Zurück zum Zitat Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol Mech Dis. 2011;6:479–507. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol Mech Dis. 2011;6:479–507.
16.
Zurück zum Zitat Kupfer SS, Anderson JR, Hooker S, Skol A, Kittles RA, Keku TO, Sandler RS, Ellis NA. Genetic heterogeneity in colorectal cancer associations between African and European Americans. Gastroenterol. 2010;139(5):1677--85. Kupfer SS, Anderson JR, Hooker S, Skol A, Kittles RA, Keku TO, Sandler RS, Ellis NA. Genetic heterogeneity in colorectal cancer associations between African and European Americans. Gastroenterol. 2010;139(5):1677--85.
17.
Zurück zum Zitat Kang GH. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med. 2011;135(6):698–703.PubMed Kang GH. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med. 2011;135(6):698–703.PubMed
18.
Zurück zum Zitat Lee AJX, Endesfelder D, Rowan A, Walther A, Birkbak NJ, Futreal PA, et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 2011;71:1858–70.PubMedCentralPubMed Lee AJX, Endesfelder D, Rowan A, Walther A, Birkbak NJ, Futreal PA, et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 2011;71:1858–70.PubMedCentralPubMed
19.
20.
Zurück zum Zitat Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol. 2000;190(4):412–6.PubMed Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol. 2000;190(4):412–6.PubMed
21.
Zurück zum Zitat Lenglauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623–7. Lenglauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623–7.
22.
Zurück zum Zitat Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005;11(23):8332–40.PubMed Benatti P, Gafà R, Barana D, Marino M, Scarselli A, Pedroni M, et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005;11(23):8332–40.PubMed
23.
Zurück zum Zitat Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248.PubMed Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58(22):5248.PubMed
24.
Zurück zum Zitat World Cancer Research Fund and American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer Research; 2007. World Cancer Research Fund and American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer Research; 2007.
25.
Zurück zum Zitat Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science. 1994;263(5153):1625–9.PubMed Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a mutL homolog in hereditary colon cancer. Science. 1994;263(5153):1625–9.PubMed
26.
Zurück zum Zitat Wilmink ABM. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum. 1997;40(4):483–93.PubMed Wilmink ABM. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum. 1997;40(4):483–93.PubMed
27.
Zurück zum Zitat Jeter JM, Kohlmann W, Gruber SB. Genetics of colorectal cancer. Oncology. 2006;20(3):269–76.PubMed Jeter JM, Kohlmann W, Gruber SB. Genetics of colorectal cancer. Oncology. 2006;20(3):269–76.PubMed
28.
Zurück zum Zitat Ruschoff J, Dietmaier W, Luttges J, et al. Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. Am J Pathol. 1997;150:1815–25.PubMedCentralPubMed Ruschoff J, Dietmaier W, Luttges J, et al. Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. Am J Pathol. 1997;150:1815–25.PubMedCentralPubMed
29.
Zurück zum Zitat Cederquist, K. (2005). Genetic and epidemiological studies of hereditary colorectal cancer. Norrlands Universitetssjukhus Cederquist, K. (2005). Genetic and epidemiological studies of hereditary colorectal cancer. Norrlands Universitetssjukhus
30.
Zurück zum Zitat Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812–6.PubMed Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812–6.PubMed
31.
Zurück zum Zitat Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–60.PubMed Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–60.PubMed
32.
Zurück zum Zitat Vilar E & Gruber SB. Microsatellite instability in colorectal cancer—the stable evidence Nat Rev Clin Oncol. 2010;7(3):153--62. Vilar E & Gruber SB. Microsatellite instability in colorectal cancer—the stable evidence Nat Rev Clin Oncol. 2010;7(3):153--62.
33.
Zurück zum Zitat Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988–93.PubMed Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988–93.PubMed
34.
Zurück zum Zitat Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23:29–39.PubMed Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23:29–39.PubMed
35.
Zurück zum Zitat Ang PW, Loh M, Liem N, Lim PL, Grieu F, Vaithilingam A, et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer. 2010;10:227.PubMedCentralPubMed Ang PW, Loh M, Liem N, Lim PL, Grieu F, Vaithilingam A, et al. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer. 2010;10:227.PubMedCentralPubMed
36.
Zurück zum Zitat Toyota M, Ahuja N, Ohe-Toyota M, Herman J, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681–6.PubMedCentralPubMed Toyota M, Ahuja N, Ohe-Toyota M, Herman J, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681–6.PubMedCentralPubMed
37.
Zurück zum Zitat Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008;3(11):e3698.PubMedCentralPubMed Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008;3(11):e3698.PubMedCentralPubMed
38.
Zurück zum Zitat Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–93.PubMed Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–93.PubMed
39.
Zurück zum Zitat Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008;68(20):8541–6.PubMed Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008;68(20):8541–6.PubMed
40.
Zurück zum Zitat Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002;122(5):1376–87.PubMed Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002;122(5):1376–87.PubMed
41.
Zurück zum Zitat Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2013;73(2):725–35. Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2013;73(2):725–35.
42.
Zurück zum Zitat Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007;21:2525–38.PubMed Rustgi AK. The genetics of hereditary colon cancer. Genes Dev. 2007;21:2525–38.PubMed
43.
Zurück zum Zitat Ahnen DJ. The genetic basis of colorectal cancer risk. Adv Intern Med. 1996;41:531–52.PubMed Ahnen DJ. The genetic basis of colorectal cancer risk. Adv Intern Med. 1996;41:531–52.PubMed
44.
Zurück zum Zitat Yeatman TJ: Colon cancer. Encyclopedia of Life Sciences; 2001. Macmillan Publishers. p. 1–6. Yeatman TJ: Colon cancer. Encyclopedia of Life Sciences; 2001. Macmillan Publishers. p. 1–6.
45.
Zurück zum Zitat Pappou EP and Ahuja N. The role of oncogenes in gastrointestinal cancer. Gastrointest. Cancer Res. 2010;2(Suppl 1):S2–S15. Pappou EP and Ahuja N. The role of oncogenes in gastrointestinal cancer. Gastrointest. Cancer Res. 2010;2(Suppl 1):S2–S15.
46.
Zurück zum Zitat Renkonen ET. Genetic basis of hereditary colorectal cancers. Helsinki University Biomedical Dissertations #75,9–12. Renkonen ET. Genetic basis of hereditary colorectal cancers. Helsinki University Biomedical Dissertations #75,9–12.
47.
Zurück zum Zitat Klingelhutz AJ, Hedrick L, Cho KR, McDougall JK. The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene. 1995;10:1581–6.PubMed Klingelhutz AJ, Hedrick L, Cho KR, McDougall JK. The DCC gene suppresses the malignant phenotype of transformed human epithelial cells. Oncogene. 1995;10:1581–6.PubMed
48.
Zurück zum Zitat Bishop JM. The enemies within: the genesis of retrovirus oncogenes. Cell. 1982;23:5–7. Bishop JM. The enemies within: the genesis of retrovirus oncogenes. Cell. 1982;23:5–7.
49.
Zurück zum Zitat Olivero M, Valente G, Bardelli A, Longati P, Ferrero N, Cracco C, et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer. 1999;82:640–3.PubMed Olivero M, Valente G, Bardelli A, Longati P, Ferrero N, Cracco C, et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int J Cancer. 1999;82:640–3.PubMed
50.
Zurück zum Zitat Alitalo K, Schwab M, Lin CC, Varmus HE, Bishop JM. Homogenously staining chromosomal regions contain amplified copies of an abundant expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A. 1983;80:1707.PubMedCentralPubMed Alitalo K, Schwab M, Lin CC, Varmus HE, Bishop JM. Homogenously staining chromosomal regions contain amplified copies of an abundant expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A. 1983;80:1707.PubMedCentralPubMed
51.
Zurück zum Zitat Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001;20:5595–610.PubMed Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001;20:5595–610.PubMed
52.
Zurück zum Zitat Rabbitts TH. Chromosomal translocations in human cancer. Nature. 1994;372:143.PubMed Rabbitts TH. Chromosomal translocations in human cancer. Nature. 1994;372:143.PubMed
53.
Zurück zum Zitat Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–65.PubMed Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459–65.PubMed
54.
Zurück zum Zitat Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298–303.PubMed Forrester K, Almoguera C, Han K, et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature. 1987;327:298–303.PubMed
55.
Zurück zum Zitat Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 1993;260:85–8.PubMed Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science. 1993;260:85–8.PubMed
56.
Zurück zum Zitat Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J Gastroenterol. 2006;41(3):185–92.PubMed Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J Gastroenterol. 2006;41(3):185–92.PubMed
57.
Zurück zum Zitat Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.PubMed Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.PubMed
58.
Zurück zum Zitat Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–13.PubMed Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–13.PubMed
59.
Zurück zum Zitat Chan TL, Zhao W, Leung SY, Yuen ST. Cancer Genome Project. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res. 2003;63:4878–81.PubMed Chan TL, Zhao W, Leung SY, Yuen ST. Cancer Genome Project. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res. 2003;63:4878–81.PubMed
60.
Zurück zum Zitat Lorentz O, Cadoret A, Duluc I, et al. Downregulation of the colon tumour-suppressor homeobox gene Cdx-2 by oncogenic ras. Oncogene. 1999;18:87–92.PubMed Lorentz O, Cadoret A, Duluc I, et al. Downregulation of the colon tumour-suppressor homeobox gene Cdx-2 by oncogenic ras. Oncogene. 1999;18:87–92.PubMed
61.
Zurück zum Zitat Guan RJ, Fu Y, Holt PR, Pardee AB. Association of Kras mutations with p16 methylation in human colon cancer. Gastroenterology. 1999;116:1063–71.PubMed Guan RJ, Fu Y, Holt PR, Pardee AB. Association of Kras mutations with p16 methylation in human colon cancer. Gastroenterology. 1999;116:1063–71.PubMed
62.
Zurück zum Zitat Sameer AS, Chowdri NA, Abdullah S, Shah ZA, Siddiqi MA. Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. Indian J Cancer. 2009;46:219–25.PubMed Sameer AS, Chowdri NA, Abdullah S, Shah ZA, Siddiqi MA. Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. Indian J Cancer. 2009;46:219–25.PubMed
63.
Zurück zum Zitat Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.PubMed Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.PubMed
64.
Zurück zum Zitat Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101:1308–24.PubMedCentralPubMed Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101:1308–24.PubMedCentralPubMed
65.
Zurück zum Zitat Calistri D, Rengucci C, Seymour I, Leonardi E, Truini M, Malacarne D, et al. KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. Anal Cell Pathol. 2006;28(4):161–6. Calistri D, Rengucci C, Seymour I, Leonardi E, Truini M, Malacarne D, et al. KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic colorectal cancer progression. Anal Cell Pathol. 2006;28(4):161–6.
66.
Zurück zum Zitat Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65(14):6063.PubMed Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65(14):6063.PubMed
67.
Zurück zum Zitat Sameer AS. Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir. Tumor Biol. 2013;34(3):1301–15. Sameer AS. Colorectal cancer: a researcher’s perspective of the molecular angel’s gone eccentric in the Vale of Kashmir. Tumor Biol. 2013;34(3):1301–15.
69.
Zurück zum Zitat Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.PubMed Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.PubMed
70.
Zurück zum Zitat Carson JD, AllerG V, Lehr R, Sinnamon RH, Kirkpatrick RB, et al. Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. J Biochem. 2008;409:519–24. Carson JD, AllerG V, Lehr R, Sinnamon RH, Kirkpatrick RB, et al. Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. J Biochem. 2008;409:519–24.
71.
Zurück zum Zitat Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62.PubMed Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62.PubMed
72.
Zurück zum Zitat Gardner L, Lee L, and Dang C. The c-Myc oncogenic transcription factor. Encyclopedia of Cancer. p. 1–13. Gardner L, Lee L, and Dang C. The c-Myc oncogenic transcription factor. Encyclopedia of Cancer. p. 1–13.
73.
Zurück zum Zitat De Pinho R et al. Myc family of cellular oncogenes. J Cell Biochem. 1987;33(4):257–66. De Pinho R et al. Myc family of cellular oncogenes. J Cell Biochem. 1987;33(4):257–66.
74.
Zurück zum Zitat Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18(19):3004–16.PubMed Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18(19):3004–16.PubMed
75.
Zurück zum Zitat Dang CV et al. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253–64.PubMed Dang CV et al. The c-Myc target gene network. Semin Cancer Biol. 2006;16(4):253–64.PubMed
77.
Zurück zum Zitat Erisman MD et al. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol Cell Biol. 1985;5(8):1969–76.PubMedCentralPubMed Erisman MD et al. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol Cell Biol. 1985;5(8):1969–76.PubMedCentralPubMed
78.
Zurück zum Zitat Sikora K et al. c-myc oncogene expression in colorectal cancer. Cancer. 1987;59(7):1289–95.PubMed Sikora K et al. c-myc oncogene expression in colorectal cancer. Cancer. 1987;59(7):1289–95.PubMed
79.
Zurück zum Zitat Monnat M et al. Prognostic implications of expression of the cellular genes myc, fos, Ha-ras and Ki-ras in colon carcinoma. Int J Cancer. 1987;40(3):293–9.PubMed Monnat M et al. Prognostic implications of expression of the cellular genes myc, fos, Ha-ras and Ki-ras in colon carcinoma. Int J Cancer. 1987;40(3):293–9.PubMed
80.
Zurück zum Zitat Yokota J et al. Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science. 1986;231(4735):261–5.PubMed Yokota J et al. Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science. 1986;231(4735):261–5.PubMed
81.
Zurück zum Zitat He TC et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–12.PubMed He TC et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281(5382):1509–12.PubMed
82.
Zurück zum Zitat Stewart J et al. Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer. 1986;53(1):1–6.PubMedCentralPubMed Stewart J et al. Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer. 1986;53(1):1–6.PubMedCentralPubMed
83.
Zurück zum Zitat Pavelic ZP et al. High c-myc protein expression in benign colorectal lesions correlates with the degree of dysplasia. Anticancer Res. 1992;12(1):171–5.PubMed Pavelic ZP et al. High c-myc protein expression in benign colorectal lesions correlates with the degree of dysplasia. Anticancer Res. 1992;12(1):171–5.PubMed
84.
Zurück zum Zitat Sundaresan V et al. Abnormal distribution of c-myc oncogene product in familial adenomatous polyposis. J Clin Pathol. 1987;40(11):1274–81.PubMedCentralPubMed Sundaresan V et al. Abnormal distribution of c-myc oncogene product in familial adenomatous polyposis. J Clin Pathol. 1987;40(11):1274–81.PubMedCentralPubMed
85.
Zurück zum Zitat Rochlitz CF, Herrmann R, de Kant E. Overexpression and amplification of c-myc during progression of human colorectal cancer. Oncology. 1996;53(6):448–54.PubMed Rochlitz CF, Herrmann R, de Kant E. Overexpression and amplification of c-myc during progression of human colorectal cancer. Oncology. 1996;53(6):448–54.PubMed
86.
Zurück zum Zitat Heerdt BG et al. Aggressive subtypes of human colorectal tumors frequently exhibit amplification of the c-myc gene. Oncogene. 1991;6(1):125–9.PubMed Heerdt BG et al. Aggressive subtypes of human colorectal tumors frequently exhibit amplification of the c-myc gene. Oncogene. 1991;6(1):125–9.PubMed
87.
Zurück zum Zitat Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24.PubMedCentralPubMed Alao JP. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007;6:24.PubMedCentralPubMed
88.
Zurück zum Zitat Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999;96:5522–7.PubMedCentralPubMed Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999;96:5522–7.PubMedCentralPubMed
89.
Zurück zum Zitat Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398:422–6.PubMed Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999;398:422–6.PubMed
90.
Zurück zum Zitat Arber N et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology. 1996;110(3):669–74.PubMed Arber N et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology. 1996;110(3):669–74.PubMed
91.
Zurück zum Zitat Mc Kay JA et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer. 2000;88(1):77–81. Mc Kay JA et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer. 2000;88(1):77–81.
92.
Zurück zum Zitat Nosho K et al. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology. 2008;53(5):588–98.PubMedCentralPubMed Nosho K et al. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology. 2008;53(5):588–98.PubMedCentralPubMed
93.
Zurück zum Zitat Ogino S et al. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res. 2009;15(13):4431–8.PubMedCentralPubMed Ogino S et al. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res. 2009;15(13):4431–8.PubMedCentralPubMed
94.
Zurück zum Zitat Sameer AS, Parray FQ, Dar MA, Nissar S, Banday MZ, Rasool S, GM Gulzar, Chowdri NA and Siddiqi MA. Cyclin D1 G870A polymorphism and risk of colorectal cancer: a case control study. Mol Med Reports; 2013;7(3):811--5. Sameer AS, Parray FQ, Dar MA, Nissar S, Banday MZ, Rasool S, GM Gulzar, Chowdri NA and Siddiqi MA. Cyclin D1 G870A polymorphism and risk of colorectal cancer: a case control study. Mol Med Reports; 2013;7(3):811--5.
95.
Zurück zum Zitat Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309(5967):418–25.PubMed Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309(5967):418–25.PubMed
96.
Zurück zum Zitat Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discovery Medicine, 2011;12(66):419--32 Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discovery Medicine, 2011;12(66):419--32
97.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;22:337–45. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;22:337–45.
98.
Zurück zum Zitat Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–8.PubMed Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201–8.PubMed
99.
Zurück zum Zitat Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001;92:1331–46.PubMed Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. 2001;92:1331–46.PubMed
100.
Zurück zum Zitat Sirvent A, Benistant C, Roche S. Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res. 2012;2(4):357–71.PubMedCentralPubMed Sirvent A, Benistant C, Roche S. Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer. Am J Cancer Res. 2012;2(4):357–71.PubMedCentralPubMed
101.
Zurück zum Zitat Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13:513–609.PubMed Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13:513–609.PubMed
102.
Zurück zum Zitat Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337–58.PubMed Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337–58.PubMed
103.
Zurück zum Zitat Han NM, Curley SA, Gallick GE. Differential activation of pp 60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. Clin Cancer Res. 1996;2:1397–404.PubMed Han NM, Curley SA, Gallick GE. Differential activation of pp 60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. Clin Cancer Res. 1996;2:1397–404.PubMed
104.
Zurück zum Zitat Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 2002;94:344–51.PubMed Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 2002;94:344–51.PubMed
105.
Zurück zum Zitat Park WS, Oh RR, Park JY, Kim PJ, Shin MS, Lee JH, et al. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol. 2001;193:483–90.PubMed Park WS, Oh RR, Park JY, Kim PJ, Shin MS, Lee JH, et al. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol. 2001;193:483–90.PubMed
106.
Zurück zum Zitat Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science. 1998;280:596–9.PubMed Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science. 1998;280:596–9.PubMed
107.
Zurück zum Zitat Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol. 1998;8:573–81.PubMed Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol. 1998;8:573–81.PubMed
108.
Zurück zum Zitat Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 1998;17:1371–84.PubMedCentralPubMed Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J. 1998;17:1371–84.PubMedCentralPubMed
109.
Zurück zum Zitat Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 1996;10:1443–54.PubMed Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 1996;10:1443–54.PubMed
110.
Zurück zum Zitat Fevr T, Robine S, Louvard D, Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol. 2007;27:7551–9.PubMedCentralPubMed Fevr T, Robine S, Louvard D, Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol Cell Biol. 2007;27:7551–9.PubMedCentralPubMed
111.
Zurück zum Zitat Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787–90.PubMed Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275:1787–90.PubMed
112.
Zurück zum Zitat Wagenaar RA, Crawford HC, Matrisian LM. Stabilized beta-catenin immortalizes colonic epithelial cells. Cancer Res. 2001;61:2097–104.PubMed Wagenaar RA, Crawford HC, Matrisian LM. Stabilized beta-catenin immortalizes colonic epithelial cells. Cancer Res. 2001;61:2097–104.PubMed
113.
Zurück zum Zitat Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998;58:1130–4.PubMed Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998;58:1130–4.PubMed
114.
Zurück zum Zitat Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108:837–47.PubMed Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108:837–47.PubMed
115.
Zurück zum Zitat Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14:1837–51.PubMed Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14:1837–51.PubMed
116.
Zurück zum Zitat Sameer AS, Shah ZA, Abdullah S, Chowdri NA, Siddiqi MA. Analysis of molecular aberrations of Wnt pathway gladiators in colorectal cancer in the Kashmiri population. Hum Genomics. 2011;5(5):441–52.PubMedCentral Sameer AS, Shah ZA, Abdullah S, Chowdri NA, Siddiqi MA. Analysis of molecular aberrations of Wnt pathway gladiators in colorectal cancer in the Kashmiri population. Hum Genomics. 2011;5(5):441–52.PubMedCentral
117.
Zurück zum Zitat Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis. 2005;26:2031–45.PubMed Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis. 2005;26:2031–45.PubMed
118.
Zurück zum Zitat Knudson AG. Hereditary cancer, oncogenes and antioncogenes. Cancer Res. 1985;45:1437–43.PubMed Knudson AG. Hereditary cancer, oncogenes and antioncogenes. Cancer Res. 1985;45:1437–43.PubMed
119.
Zurück zum Zitat Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci U S A. 1993;90(109):14–21. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci U S A. 1993;90(109):14–21.
120.
Zurück zum Zitat Levitt NC, Hickson ID. Caretaker tumour suppressor genes that defend genome integrity. Trends Mol Med. 2002;8:179–86.PubMed Levitt NC, Hickson ID. Caretaker tumour suppressor genes that defend genome integrity. Trends Mol Med. 2002;8:179–86.PubMed
121.
Zurück zum Zitat Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol. 2000;18:1967–79.PubMed Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol. 2000;18:1967–79.PubMed
122.
Zurück zum Zitat Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17:45–51.PubMed Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007;17:45–51.PubMed
123.
Zurück zum Zitat Brocardo M, Henderson S. APC shuttling to the membrane, nucleus, and beyond. Trends Cell Biol. 2009;18:587–96. Brocardo M, Henderson S. APC shuttling to the membrane, nucleus, and beyond. Trends Cell Biol. 2009;18:587–96.
124.
Zurück zum Zitat Lynch HT, De La Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32.PubMed Lynch HT, De La Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32.PubMed
125.
Zurück zum Zitat Worthley DL, Whitehall VL, Spring KJ, Leggett BA. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol. 2007;13:3784–91.PubMed Worthley DL, Whitehall VL, Spring KJ, Leggett BA. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol. 2007;13:3784–91.PubMed
126.
Zurück zum Zitat Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249:912–25.PubMed Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249:912–25.PubMed
127.
Zurück zum Zitat Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 2008;7:979–87.PubMed Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 2008;7:979–87.PubMed
128.
Zurück zum Zitat Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217–21.PubMed Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989;244:217–21.PubMed
129.
Zurück zum Zitat Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogenes. 2005;24:2899–908. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogenes. 2005;24:2899–908.
130.
Zurück zum Zitat Hung J, Anderson R. p53: functions, mutations and sarcomas. Acta Orthop Scand Suppl. 1997;273:68–73.PubMed Hung J, Anderson R. p53: functions, mutations and sarcomas. Acta Orthop Scand Suppl. 1997;273:68–73.PubMed
131.
Zurück zum Zitat Sameer AS, ul Rehman AA, Pandith AA, Syeed N, Shah ZA, Chowdhri NA, et al. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol. 2009;15(4):244–52.PubMedCentralPubMed Sameer AS, ul Rehman AA, Pandith AA, Syeed N, Shah ZA, Chowdhri NA, et al. Molecular gate keepers succumb to gene aberrations in colorectal cancer in Kashmiri population, revealing a high incidence area. Saudi J Gastroenterol. 2009;15(4):244–52.PubMedCentralPubMed
132.
Zurück zum Zitat Molecular mechanisms involved in colorectal cancer initiation and progression. Oncology Programme 2007 Scientific Report, pp. 118–121. Molecular mechanisms involved in colorectal cancer initiation and progression. Oncology Programme 2007 Scientific Report, pp. 118–121.
133.
Zurück zum Zitat Muñoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, et al. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by APC mutation. Cancer Res. 2006;66(20):9837–44.PubMed Muñoz NM, Upton M, Rojas A, Washington MK, Lin L, Chytil A, et al. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by APC mutation. Cancer Res. 2006;66(20):9837–44.PubMed
134.
Zurück zum Zitat Massagué J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295–309.PubMed Massagué J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295–309.PubMed
135.
Zurück zum Zitat Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J, et al. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 1998;58(14):3101–4.PubMed Grady WM, Rajput A, Myeroff L, Liu DF, Kwon K, Willis J, et al. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res. 1998;58(14):3101–4.PubMed
136.
Zurück zum Zitat Samanta D, Datta PK. Alterations in the Smad pathway in human cancers. Front Biosci. 2012;17:1281–93. Samanta D, Datta PK. Alterations in the Smad pathway in human cancers. Front Biosci. 2012;17:1281–93.
137.
Zurück zum Zitat Engel ME, Datta PK, Moses HL. Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. J Cell Biochem Suppl. 1998;30–31:111–22.PubMed Engel ME, Datta PK, Moses HL. Signal transduction by transforming growth factor-beta: a cooperative paradigm with extensive negative regulation. J Cell Biochem Suppl. 1998;30–31:111–22.PubMed
138.
Zurück zum Zitat Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, et al. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology. 2010;138(3):969–80.PubMedCentralPubMed Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, et al. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology. 2010;138(3):969–80.PubMedCentralPubMed
139.
Zurück zum Zitat Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res. 2005;11:2606–11.PubMed Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP, et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res. 2005;11:2606–11.PubMed
140.
Zurück zum Zitat Sameer AS, Chowdri NA, Syeed N, Banday MZ, Shah ZA, Siddiqi MA. SMAD4—molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. BMC Cancer. 2010;10:300.PubMedCentralPubMed Sameer AS, Chowdri NA, Syeed N, Banday MZ, Shah ZA, Siddiqi MA. SMAD4—molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. BMC Cancer. 2010;10:300.PubMedCentralPubMed
141.
Zurück zum Zitat Morán A, Ortega P, de Juan C, Fernández-Marcelo T, Frías C, Sánchez-Pernaute A, et al. Differential colorectal carcinogenesis: molecular basis and clinical relevance. World J Gastrointest Oncol. 2010;2(3):151–8.PubMedCentralPubMed Morán A, Ortega P, de Juan C, Fernández-Marcelo T, Frías C, Sánchez-Pernaute A, et al. Differential colorectal carcinogenesis: molecular basis and clinical relevance. World J Gastrointest Oncol. 2010;2(3):151–8.PubMedCentralPubMed
142.
Zurück zum Zitat Akkiprik M, Ataizi-Çelikel Ç, Düşünceli F, Sönmez Ö, Güllüoglu BM, Sav A, et al. Clinical significance of p53 K-ras and DCC gene alterations in the stage I–II colorectal cancers. J Gastrointest Liver Dis. 2007;16:11–7. Akkiprik M, Ataizi-Çelikel Ç, Düşünceli F, Sönmez Ö, Güllüoglu BM, Sav A, et al. Clinical significance of p53 K-ras and DCC gene alterations in the stage I–II colorectal cancers. J Gastrointest Liver Dis. 2007;16:11–7.
143.
Zurück zum Zitat Itoh F, Hinoda Y, Ohe M, et al. Decreased expression of DCC mRNA in human colorectal cancers. Int J Cancer. 1993;53:260–3.PubMed Itoh F, Hinoda Y, Ohe M, et al. Decreased expression of DCC mRNA in human colorectal cancers. Int J Cancer. 1993;53:260–3.PubMed
144.
Zurück zum Zitat Iino H, Fukayama M, Maeda Y, et al. Molecular genetics for clinical management of colorectal carcinoma. Cancer. 1994;73:1324–31.PubMed Iino H, Fukayama M, Maeda Y, et al. Molecular genetics for clinical management of colorectal carcinoma. Cancer. 1994;73:1324–31.PubMed
145.
Zurück zum Zitat Saito M, Yamaguchi A, Goi T, et al. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis. Oncology. 1999;56:134–41.PubMed Saito M, Yamaguchi A, Goi T, et al. Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis. Oncology. 1999;56:134–41.PubMed
146.
Zurück zum Zitat Gotley DC, Reeder JA, Fawcett J, et al. The deleted in colon cancer (DCC) gene is consistently expressed in colorectal cancers and metastases. Oncogene. 1996;13:787–95.PubMed Gotley DC, Reeder JA, Fawcett J, et al. The deleted in colon cancer (DCC) gene is consistently expressed in colorectal cancers and metastases. Oncogene. 1996;13:787–95.PubMed
147.
Zurück zum Zitat Tanaka K, Oshimura M, Kikuchi R, Seki M, Hayashi T, Miyaki M. Suppression of tumourigenicity in human colon carcinoma cells by introduction of normal chromosome 5 or 18. Nature. 1991;349:340–2.PubMed Tanaka K, Oshimura M, Kikuchi R, Seki M, Hayashi T, Miyaki M. Suppression of tumourigenicity in human colon carcinoma cells by introduction of normal chromosome 5 or 18. Nature. 1991;349:340–2.PubMed
148.
Zurück zum Zitat Kathleen RC, Jonathan DO, Jonathan WS, Lora H, Eric RF, Antonette CP, et al. The DCC gene: structural analysis and mutations in colorectal carcinoma. Genomics. 1994;19:525–31. Kathleen RC, Jonathan DO, Jonathan WS, Lora H, Eric RF, Antonette CP, et al. The DCC gene: structural analysis and mutations in colorectal carcinoma. Genomics. 1994;19:525–31.
149.
Zurück zum Zitat Christelle F, Xin Y, Laure G, Ve'ronique C, Hwain S, Dale EB, et al. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. PNAS. 2001;98:3416–21. Christelle F, Xin Y, Laure G, Ve'ronique C, Hwain S, Dale EB, et al. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. PNAS. 2001;98:3416–21.
150.
Zurück zum Zitat Adrienne VD, Joseph S, Ellen F, Molly DS. The Drosophila netrin receptor frazzled/DCC functions as an invasive tumor suppressor. BMC Dev Biol. 2011;11:41. Adrienne VD, Joseph S, Ellen F, Molly DS. The Drosophila netrin receptor frazzled/DCC functions as an invasive tumor suppressor. BMC Dev Biol. 2011;11:41.
151.
Zurück zum Zitat Meimei L, Peiling L, Baoxin L, Changmin L, Rujin Z, Chunjie H. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells. Med. Oncol. 2011;28(1):282–9. Meimei L, Peiling L, Baoxin L, Changmin L, Rujin Z, Chunjie H. Lost expression of DCC gene in ovarian cancer and its inhibition in ovarian cancer cells. Med. Oncol. 2011;28(1):282–9.
152.
Zurück zum Zitat Mustafa A, Çigdem A, Fikret D, Özgür S, Bahadýr MG, Aydin S, et al. Clinical significance of p53, K-ras and DCC gene alterations in the stage I–II colorectal cancers. J Gastrointest Liver Dis. 2007;16:11–7. Mustafa A, Çigdem A, Fikret D, Özgür S, Bahadýr MG, Aydin S, et al. Clinical significance of p53, K-ras and DCC gene alterations in the stage I–II colorectal cancers. J Gastrointest Liver Dis. 2007;16:11–7.
153.
Zurück zum Zitat Shekarabi M, Kennedy TE. The netrin-1 receptor DCC promotes filopodia formation and cell spreading by activating Cdc42 and Rac1. Mol Cell Neurosci. 2002;19:1–17.PubMed Shekarabi M, Kennedy TE. The netrin-1 receptor DCC promotes filopodia formation and cell spreading by activating Cdc42 and Rac1. Mol Cell Neurosci. 2002;19:1–17.PubMed
154.
Zurück zum Zitat Khan NP, Pandith AA, Hussain MU, Yousuf A, Khan MS, Siddiqi MA, et al. Loss of heterozygosity (LOH) of deleted in colorectal cancer (DCC) gene and predisposition to colorectal cancer: significant association in colorectal cancer patients of Kashmir. J Cancer Res Exp Oncol. 2011;3(8):88–94. Khan NP, Pandith AA, Hussain MU, Yousuf A, Khan MS, Siddiqi MA, et al. Loss of heterozygosity (LOH) of deleted in colorectal cancer (DCC) gene and predisposition to colorectal cancer: significant association in colorectal cancer patients of Kashmir. J Cancer Res Exp Oncol. 2011;3(8):88–94.
155.
Zurück zum Zitat Naguib A, Cooke JC, Happerfield L, Kerr L, Gay LJ, Luben RN, et al. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk Study: associations with clinicopathological and dietary factors. BMC Cancer. 2011;11:123.PubMedCentralPubMed Naguib A, Cooke JC, Happerfield L, Kerr L, Gay LJ, Luben RN, et al. Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk Study: associations with clinicopathological and dietary factors. BMC Cancer. 2011;11:123.PubMedCentralPubMed
156.
Zurück zum Zitat Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.PubMed Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–7.PubMed
157.
Zurück zum Zitat Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–62.PubMed Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–62.PubMed
158.
Zurück zum Zitat Li DM, Sun H. TEP1 encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β. Cancer Res. 1997;57:2124–9.PubMed Li DM, Sun H. TEP1 encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor β. Cancer Res. 1997;57:2124–9.PubMed
159.
Zurück zum Zitat Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64–7.PubMed Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16:64–7.PubMed
160.
Zurück zum Zitat Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, et al. Germline mutations in PTEN are present in Bannayan–Zonana syndrome. Nat Genet. 1997;16:333–4.PubMed Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, et al. Germline mutations in PTEN are present in Bannayan–Zonana syndrome. Nat Genet. 1997;16:333–4.PubMed
161.
Zurück zum Zitat Chang JG, Chen YJ, Perng LI, Wang NM, Kao MC, Yang TY, et al. Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract. Eur J Cancer. 1999;35(4):647–51.PubMed Chang JG, Chen YJ, Perng LI, Wang NM, Kao MC, Yang TY, et al. Mutation analysis of the PTEN/MMAC1 gene in cancers of the digestive tract. Eur J Cancer. 1999;35(4):647–51.PubMed
162.
Zurück zum Zitat Danielsen SA, Lind GE, Bjornslett M, Meling GI, Rognum TO, Heim S, Lothe RA: Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability- and TP53 mutation status. Hum Mutat. 2008;29(11):E252--62. Danielsen SA, Lind GE, Bjornslett M, Meling GI, Rognum TO, Heim S, Lothe RA: Novel mutations of the suppressor gene PTEN in colorectal carcinomas stratified by microsatellite instability- and TP53 mutation status. Hum Mutat. 2008;29(11):E252--62.
163.
Zurück zum Zitat Dicuonzo G, Angeletti S, Garcia-Foncillas J, Brugarolas A, Okrouzhnov Y, Santini D, et al. Colorectal carcinomas and PTEN/MMAC1 gene mutations. Clin Cancer Res. 2001;7(12):4049–53.PubMed Dicuonzo G, Angeletti S, Garcia-Foncillas J, Brugarolas A, Okrouzhnov Y, Santini D, et al. Colorectal carcinomas and PTEN/MMAC1 gene mutations. Clin Cancer Res. 2001;7(12):4049–53.PubMed
164.
Zurück zum Zitat Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004;64(9):3014–21.PubMed Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell JM, Wasserman L, et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004;64(9):3014–21.PubMed
165.
Zurück zum Zitat Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C, et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene. 2004;23(2):617–28.PubMed Nassif NT, Lobo GP, Wu X, Henderson CJ, Morrison CD, Eng C, et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene. 2004;23(2):617–28.PubMed
166.
Zurück zum Zitat Wang ZJ, Taylor F, Churchman M, Norbury G, Tomlinson I. Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes. Am J Pathol. 1998;153(2):363–6.PubMedCentralPubMed Wang ZJ, Taylor F, Churchman M, Norbury G, Tomlinson I. Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes. Am J Pathol. 1998;153(2):363–6.PubMedCentralPubMed
167.
Zurück zum Zitat Guanti G, Resta N, Simone C, Cariola F, Demma I, Fiorente P, et al. Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet. 2000;9(2):283–7.PubMed Guanti G, Resta N, Simone C, Cariola F, Demma I, Fiorente P, et al. Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis. Hum Mol Genet. 2000;9(2):283–7.PubMed
168.
Zurück zum Zitat Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A, et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol. 2002;161(2):439–47.PubMedCentralPubMed Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A, et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol. 2002;161(2):439–47.PubMedCentralPubMed
170.
Zurück zum Zitat Chiou SK, Jones MK, Tarnawski AS. Survivin—an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit. 2003;9(4):143–7. Chiou SK, Jones MK, Tarnawski AS. Survivin—an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit. 2003;9(4):143–7.
171.
Zurück zum Zitat Miller L. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. 1999;9:323–8.PubMed Miller L. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. 1999;9:323–8.PubMed
172.
Zurück zum Zitat O’Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A. 2000;97:13103–7.PubMedCentralPubMed O’Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A. 2000;97:13103–7.PubMedCentralPubMed
173.
Zurück zum Zitat Ikeguchi M, Yamaguchi K, Kaibara N. Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol. 2003;24:40–5.PubMed Ikeguchi M, Yamaguchi K, Kaibara N. Survivin gene expression positively correlates with proliferative activity of cancer cells in esophageal cancer. Tumour Biol. 2003;24:40–5.PubMed
174.
Zurück zum Zitat Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer Res. 1998;58:15–20. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer Res. 1998;58:15–20.
175.
Zurück zum Zitat Kawasaki H, Toyoda M, Shinohara H, et al. Expression of surviving correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91:2026–32.PubMed Kawasaki H, Toyoda M, Shinohara H, et al. Expression of surviving correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91:2026–32.PubMed
176.
Zurück zum Zitat Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001;32:119–25.PubMed Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001;32:119–25.PubMed
177.
Zurück zum Zitat Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10:188–93.PubMed Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10:188–93.PubMed
178.
Zurück zum Zitat Ofner D, Riehemann K, Maier H, Reidmann B, Nehoda H, Totsch M, et al. Immunohistochemically detectable Bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Br J Cancer. 1995;72:981–5.PubMedCentralPubMed Ofner D, Riehemann K, Maier H, Reidmann B, Nehoda H, Totsch M, et al. Immunohistochemically detectable Bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Br J Cancer. 1995;72:981–5.PubMedCentralPubMed
179.
Zurück zum Zitat Baretton GB, Diebold G, Christoforis G, Vogt M, Muller C, Dopfer K, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer (Phila). 1996;77:255–64. Baretton GB, Diebold G, Christoforis G, Vogt M, Muller C, Dopfer K, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer (Phila). 1996;77:255–64.
180.
Zurück zum Zitat Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995;1:1103–10.PubMed Sinicrope FA, Hart J, Michelassi F, Lee JJ. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res. 1995;1:1103–10.PubMed
181.
Zurück zum Zitat Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res. 2001;7:11–8. Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res. 2001;7:11–8.
182.
Zurück zum Zitat Pritchard DM, Potten CS, Korsmeyer SJ, et al. Damage-induced apoptosis in intestinal epithelia from bcl-2-null and bax-null mice: investigations of the mechanistic determinants of epithelial apoptosis in vivo. Oncogene. 1999;18:7287–93.PubMed Pritchard DM, Potten CS, Korsmeyer SJ, et al. Damage-induced apoptosis in intestinal epithelia from bcl-2-null and bax-null mice: investigations of the mechanistic determinants of epithelial apoptosis in vivo. Oncogene. 1999;18:7287–93.PubMed
183.
Zurück zum Zitat Pritchard DM, Print C, O’Reilly L, et al. Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine. Oncogene. 2000;19(34):3955–9.PubMed Pritchard DM, Print C, O’Reilly L, et al. Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine. Oncogene. 2000;19(34):3955–9.PubMed
184.
Zurück zum Zitat Pathan N, Marusawa H, Krajewska M, et al. TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer. JBC. 2001;276:32220–9. Pathan N, Marusawa H, Krajewska M, et al. TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer. JBC. 2001;276:32220–9.
185.
Zurück zum Zitat Poirier MC, Santella RM, Weston A. Carcinogen macromolecular adducts and their measurement. Carcinogenesis. 2000;21:353–9.PubMed Poirier MC, Santella RM, Weston A. Carcinogen macromolecular adducts and their measurement. Carcinogenesis. 2000;21:353–9.PubMed
186.
Zurück zum Zitat Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993;14:1085–9.PubMed Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993;14:1085–9.PubMed
187.
Zurück zum Zitat Bozina N, Bradamante V, Lovric M. Genetic polymorphisms of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity and cancer risk. Arh Hig Rada Toksikol. 2009;60:217–42.PubMed Bozina N, Bradamante V, Lovric M. Genetic polymorphisms of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity and cancer risk. Arh Hig Rada Toksikol. 2009;60:217–42.PubMed
188.
Zurück zum Zitat Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. Environmental and heritable factors in the causation of cancer analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.PubMed Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, et al. Environmental and heritable factors in the causation of cancer analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.PubMed
189.
Zurück zum Zitat Kury S, Buecher B, Robiou-du-Pont S, Scoul C, Sebille V, Colman H, et al. Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev. 2007;16:1460–7.PubMed Kury S, Buecher B, Robiou-du-Pont S, Scoul C, Sebille V, Colman H, et al. Combinations of cytochrome P450 gene polymorphisms enhancing the risk for sporadic colorectal cancer related to red meat consumption. Cancer Epidemiol Biomarkers Prev. 2007;16:1460–7.PubMed
190.
Zurück zum Zitat Cotterchio M et al. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:3098–107.PubMedCentralPubMed Cotterchio M et al. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:3098–107.PubMedCentralPubMed
191.
Zurück zum Zitat Bethke L et al. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer. 2007;7:123.PubMedCentralPubMed Bethke L et al. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer. 2007;7:123.PubMedCentralPubMed
192.
Zurück zum Zitat Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Carcinogenesis. 1993;14:1821–4.PubMed Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK. Carcinogenesis. 1993;14:1821–4.PubMed
193.
Zurück zum Zitat Brockmoller J, Kerb R, Drakoulis N, Staffeldt B, Roots I. Cancer Res. 1994;54:4103–11.PubMed Brockmoller J, Kerb R, Drakoulis N, Staffeldt B, Roots I. Cancer Res. 1994;54:4103–11.PubMed
194.
Zurück zum Zitat Seidegård J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Carcinogenesis. 1990;11:33–6.PubMed Seidegård J, Pero RW, Markowitz MM, Roush G, Miller DG, Beattie EJ. Carcinogenesis. 1990;11:33–6.PubMed
195.
Zurück zum Zitat Kodate C, Fukushi A, Narita T, Kudo H, Soma Y, Sato K. Jpn J Cancer Res. 1988;77:226–9. Kodate C, Fukushi A, Narita T, Kudo H, Soma Y, Sato K. Jpn J Cancer Res. 1988;77:226–9.
196.
Zurück zum Zitat Zhao ZQ, Guan QK, Yang FY, Zhao P, Zhou B, Chen ZJ. System review and meta-analysis of the relationships between five metabolic gene polymorphisms and colorectal adenoma risk. Tumour Biol. 2012;33(2):523–35.PubMed Zhao ZQ, Guan QK, Yang FY, Zhao P, Zhou B, Chen ZJ. System review and meta-analysis of the relationships between five metabolic gene polymorphisms and colorectal adenoma risk. Tumour Biol. 2012;33(2):523–35.PubMed
197.
Zurück zum Zitat Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993;14:1633.PubMed Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis. 1993;14:1633.PubMed
198.
Zurück zum Zitat Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res. 1987;47:1466.PubMed Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res. 1987;47:1466.PubMed
199.
Zurück zum Zitat Sameer AS, Nissar S, Qadri Q, Alam S, Baba SM, Siddiqi MA. Role of CYP2E1 genotypes in susceptibility to colorectal cancer in Kashmiri population. Hum Genomics. 2011;5(6):530–7.PubMedCentralPubMed Sameer AS, Nissar S, Qadri Q, Alam S, Baba SM, Siddiqi MA. Role of CYP2E1 genotypes in susceptibility to colorectal cancer in Kashmiri population. Hum Genomics. 2011;5(6):530–7.PubMedCentralPubMed
200.
Zurück zum Zitat Sameer AS, Qadri A, Siddiqi MA. GSTP1 I105V polymorphism and susceptibility to colorectal cancer in Kashmiri population. DNA Cell Biol. 2012;31(1):74–9.PubMed Sameer AS, Qadri A, Siddiqi MA. GSTP1 I105V polymorphism and susceptibility to colorectal cancer in Kashmiri population. DNA Cell Biol. 2012;31(1):74–9.PubMed
201.
Zurück zum Zitat Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241–6.PubMed Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241–6.PubMed
202.
Zurück zum Zitat Williams CS, Mann M, DuBios RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908–16.PubMed Williams CS, Mann M, DuBios RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908–16.PubMed
203.
Zurück zum Zitat Egil F. Biochemistry of cyclooxygenase (COX-2) inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37:431–502. Egil F. Biochemistry of cyclooxygenase (COX-2) inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37:431–502.
204.
Zurück zum Zitat Subbaramaiah K, Dannenberg AJ. Cyclooxygenase2: a molecular target for cancer prevention and, treatment. Trends Pharmacol Sci. 2003;24:96–102.PubMed Subbaramaiah K, Dannenberg AJ. Cyclooxygenase2: a molecular target for cancer prevention and, treatment. Trends Pharmacol Sci. 2003;24:96–102.PubMed
205.
Zurück zum Zitat Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–8.PubMed Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–8.PubMed
206.
Zurück zum Zitat Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11–21.PubMed Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11–21.PubMed
207.
Zurück zum Zitat Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55–80.PubMed Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55–80.PubMed
208.
Zurück zum Zitat Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008;14:8221–7.PubMedCentralPubMed Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008;14:8221–7.PubMedCentralPubMed
209.
Zurück zum Zitat Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803–9.PubMed Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803–9.PubMed
210.
Zurück zum Zitat Wang D, DuBois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010;29(6):781–8.PubMedCentralPubMed Wang D, DuBois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010;29(6):781–8.PubMedCentralPubMed
211.
Zurück zum Zitat Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem. 2002;277:27613–21.PubMed Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem. 2002;277:27613–21.PubMed
212.
Zurück zum Zitat Chen WS, Liu JH, Wei SJ, Liu JM, Hong CY, Yang WK. Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor. Cancer Sci. 2003;94:253–8.PubMed Chen WS, Liu JH, Wei SJ, Liu JM, Hong CY, Yang WK. Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor. Cancer Sci. 2003;94:253–8.PubMed
213.
Zurück zum Zitat Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–84.PubMed Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873–84.PubMed
214.
Zurück zum Zitat Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–90.PubMed Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–90.PubMed
216.
Zurück zum Zitat Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med. 2006;203:941–51.PubMedCentralPubMed Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med. 2006;203:941–51.PubMedCentralPubMed
217.
Zurück zum Zitat Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin–beta-catenin signaling axis. Science. 2005;310:1504–10.PubMed Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin–beta-catenin signaling axis. Science. 2005;310:1504–10.PubMed
218.
Zurück zum Zitat Wu AW, Gu J, Ji JF, Li ZF, Xu GW. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients prognosis. World J Gastroenterol. 2003;9(9):1990–4.PubMed Wu AW, Gu J, Ji JF, Li ZF, Xu GW. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients prognosis. World J Gastroenterol. 2003;9(9):1990–4.PubMed
219.
Zurück zum Zitat Müller-Decker K, Fürstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog. 2007;46:705–10.PubMed Müller-Decker K, Fürstenberger G. The cyclooxygenase-2-mediated prostaglandin signaling is causally related to epithelial carcinogenesis. Mol Carcinog. 2007;46:705–10.PubMed
220.
Zurück zum Zitat The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.
221.
Zurück zum Zitat Kim TM, Lee SH, Chung YJ. Clinical applications of next-generation sequencing in colorectal cancers. World J Gastroenterol. 2013;19(40):6784–93.PubMedCentralPubMed Kim TM, Lee SH, Chung YJ. Clinical applications of next-generation sequencing in colorectal cancers. World J Gastroenterol. 2013;19(40):6784–93.PubMedCentralPubMed
222.
Zurück zum Zitat Biancolella M, K Fortini B, Tring S, Plummer SJ, Mendoza-Fandino GA, et al. Identification and characterization of functional risk variants for colorectal cancer mapping to chromosome 11q23.1. Hum Mol Genet. 2013; doi:10.1093/hmg/ddt584. Biancolella M, K Fortini B, Tring S, Plummer SJ, Mendoza-Fandino GA, et al. Identification and characterization of functional risk variants for colorectal cancer mapping to chromosome 11q23.1. Hum Mol Genet. 2013; doi:10.​1093/​hmg/​ddt584.
223.
Zurück zum Zitat Javid G, Zargar SA, Rather S, Khan AR, Khan BA, Yattoo GN, et al. Incidence of colorectal cancer in Kashmir Valley, India. Indian J Gastroenterol. 2011;30(1):7–11.PubMed Javid G, Zargar SA, Rather S, Khan AR, Khan BA, Yattoo GN, et al. Incidence of colorectal cancer in Kashmir Valley, India. Indian J Gastroenterol. 2011;30(1):7–11.PubMed
224.
Zurück zum Zitat Fernandez-Rozadilla C, Cazier JB, Tomlinson I, Brea-Fernández A, Lamas MJ, et al. The EPICOLON Consortium, Hemminki K, Bessa X, Andreu M, Jover R, Xicola R, Llor X, Moreno V, Castells A, Castellví-Bel S, Carracedo A, Ruiz-Ponte C. A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer. Hum Genet. 2013; doi:10.1007/s00439-013-1390-4 Fernandez-Rozadilla C, Cazier JB, Tomlinson I, Brea-Fernández A, Lamas MJ, et al. The EPICOLON Consortium, Hemminki K, Bessa X, Andreu M, Jover R, Xicola R, Llor X, Moreno V, Castells A, Castellví-Bel S, Carracedo A, Ruiz-Ponte C. A genome-wide association study on copy-number variation identifies a 11q11 loss as a candidate susceptibility variant for colorectal cancer. Hum Genet. 2013; doi:10.​1007/​s00439-013-1390-4
225.
Zurück zum Zitat Rasool S, Kadla SA, Khan T, Qazi F, Shah NA, Basu J, et al. Association of a VDR gene polymorphism with risk of colorectal cancer in Kashmir. Asian Pac J Cancer Prev. 2013;14:5833–7.PubMed Rasool S, Kadla SA, Khan T, Qazi F, Shah NA, Basu J, et al. Association of a VDR gene polymorphism with risk of colorectal cancer in Kashmir. Asian Pac J Cancer Prev. 2013;14:5833–7.PubMed
226.
Zurück zum Zitat Malik MA, Gupta A, Zargar SA, Mittal B. Role of genetic variants of deleted in colorectal carcinoma (DCC) polymorphisms and esophageal and gastric cancers risk in Kashmir Valley and meta-analysis. Tumour Biol. 2013;34:3049–57.PubMed Malik MA, Gupta A, Zargar SA, Mittal B. Role of genetic variants of deleted in colorectal carcinoma (DCC) polymorphisms and esophageal and gastric cancers risk in Kashmir Valley and meta-analysis. Tumour Biol. 2013;34:3049–57.PubMed
227.
Zurück zum Zitat Nissar S, Lone TA, Banday MZ, Rasool R, Chowdri NA, Parray FQ, et al. Arg399Gln polymorphism of XRCC1 gene and risk of colorectal cancer in Kashmir: a case control study. Oncol Lett. 2013;5:959–63.PubMedCentralPubMed Nissar S, Lone TA, Banday MZ, Rasool R, Chowdri NA, Parray FQ, et al. Arg399Gln polymorphism of XRCC1 gene and risk of colorectal cancer in Kashmir: a case control study. Oncol Lett. 2013;5:959–63.PubMedCentralPubMed
228.
Zurück zum Zitat Wani HA, Beigh MA, Amin S, Bhat AA, Bhat S, Khan H, et al. Methylation profile of promoter region of p16 gene in colorectal cancer patients of Kashmir Valley. J Biol Regul Homeost Agents. 2013;27(2):297–307.PubMed Wani HA, Beigh MA, Amin S, Bhat AA, Bhat S, Khan H, et al. Methylation profile of promoter region of p16 gene in colorectal cancer patients of Kashmir Valley. J Biol Regul Homeost Agents. 2013;27(2):297–307.PubMed
229.
Zurück zum Zitat Khan NP, Pandith AA, Yousuf A, Khan NS, Khan MS, Bhat IA, et al. The XRCC1 Arg399Gln gene polymorphism and risk of colorectal cancer: a study in Kashmir. Asian Pac J Cancer Prev. 2013;14(11):6779–82.PubMed Khan NP, Pandith AA, Yousuf A, Khan NS, Khan MS, Bhat IA, et al. The XRCC1 Arg399Gln gene polymorphism and risk of colorectal cancer: a study in Kashmir. Asian Pac J Cancer Prev. 2013;14(11):6779–82.PubMed
230.
Zurück zum Zitat Wani M, Afroze D, Makhdoomi M, Hamid I, Wani B, Bhat G, et al. Promoter methylation status of DNA repair gene (hMLH1) in gastric carcinoma patients of the Kashmir Valley. Asian Pac J Cancer Prev. 2012;13(8):4177–81.PubMed Wani M, Afroze D, Makhdoomi M, Hamid I, Wani B, Bhat G, et al. Promoter methylation status of DNA repair gene (hMLH1) in gastric carcinoma patients of the Kashmir Valley. Asian Pac J Cancer Prev. 2012;13(8):4177–81.PubMed
231.
Zurück zum Zitat Shah MA, Shaff SM, Lone GN, Jan SM. Lack of influence of MGMT codon Leu84Phe and codon Ileu143Val polymorphisms on esophageal cancer risk in the Kashmir Valley. Asian Pac J Cancer Prev. 2012;13(7):3047–52.PubMed Shah MA, Shaff SM, Lone GN, Jan SM. Lack of influence of MGMT codon Leu84Phe and codon Ileu143Val polymorphisms on esophageal cancer risk in the Kashmir Valley. Asian Pac J Cancer Prev. 2012;13(7):3047–52.PubMed
232.
Zurück zum Zitat Shafia S, Qasim I, Aziz SA, Bhat IA, Nisar S, Shah ZA. Role of vitamin D receptor (VDR) polymorphisms in susceptibility to multiple myeloma in ethnic Kashmiri population. Blood Cells Mol Dis. 2013;51(1):56–60.PubMed Shafia S, Qasim I, Aziz SA, Bhat IA, Nisar S, Shah ZA. Role of vitamin D receptor (VDR) polymorphisms in susceptibility to multiple myeloma in ethnic Kashmiri population. Blood Cells Mol Dis. 2013;51(1):56–60.PubMed
Metadaten
Titel
Genetic unraveling of colorectal cancer
verfasst von
Sabha Rasool
Vamiq Rasool
Tahira Naqvi
Bashir A. Ganai
Bhahwal Ali Shah
Publikationsdatum
01.06.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1713-7

Weitere Artikel der Ausgabe 6/2014

Tumor Biology 6/2014 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.